Drug Profile
Enoximone
Alternative Names: fenoximone; MDL 17043; Perfan; Perfan®IVLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Cardiotonics; Imidazoles; Small molecules; Vasodilators
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heart failure
Most Recent Events
- 18 Nov 2006 Myogen has been acquired by Gilead Sciences
- 07 Feb 2006 Myogen Inc. has sold Myogen GmbH and the sublicense of its rights to intravenous enoximone in markets outside North America, to Wulfing Holding GmbH
- 28 Jun 2005 Data from a media release have been added to the Heart failure therapeutic trials section